A detailed history of Blueshift Asset Management, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Blueshift Asset Management, LLC holds 5,345 shares of BMY stock, worth $284,300. This represents 0.08% of its overall portfolio holdings.

Number of Shares
5,345
Holding current value
$284,300
% of portfolio
0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $215,136 - $283,231
5,345 New
5,345 $221,000
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $204,294 - $243,779
4,214 New
4,214 $216,000
Q2 2023

Aug 15, 2023

SELL
$63.71 - $70.74 $173,673 - $192,837
-2,726 Reduced 44.3%
3,428 $219,000
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $11,630 - $13,191
177 Added 2.96%
6,154 $426,000
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $409,304 - $484,674
5,977 New
5,977 $429,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $1.97 Million - $2.17 Million
-27,124 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $1.67 Million - $2 Million
27,124 New
27,124 $1.98 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $13.4 Million - $15.6 Million
-249,521 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $13.4 Million - $15.7 Million
227,131 Added 1014.43%
249,521 $14.8 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $8,110 - $8,832
131 Added 0.59%
22,390 $1.5 Million
Q1 2021

May 06, 2021

BUY
$59.34 - $66.74 $1.32 Million - $1.49 Million
22,259 New
22,259 $1.41 Million
Q1 2020

May 14, 2020

SELL
$46.4 - $67.43 $2.41 Million - $3.51 Million
-52,025 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $2.56 Million - $3.34 Million
52,025 New
52,025 $3.34 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Blueshift Asset Management, LLC Portfolio

Follow Blueshift Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueshift Asset Management, LLC with notifications on news.